Jacobs Levy Equity Management, Inc Next Cure, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $884,388 - $1.16 Million	-185,796 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $41,461 - $66,193	-7,274 Reduced 3.77%	185,796 $1.12 Million
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $899,951 - $1.07 Million	133,524 Added 224.24%	193,070 $1.3 Million
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $132,696 - $179,488	-17,460 Reduced 22.67%	59,546 $478,000
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $137,163 - $194,070	13,982 Added 22.19%	77,006 $771,000
Q4 2020 Feb 16, 2021	BUY	$9.47 - $12.43 $596,837 - $783,388	63,024 New	63,024 $687,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $26.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.